Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2023 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers...
June 28, 2022 08:00 ET | Source: Certara

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

PRINCETON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for...
April 06, 2016 09:20 ET | Source: PharmaCyte Biotech, Inc.

PharmaCyte Biotech's CEO Explains How New Clinical Trial Design Changed the GMP Certification Process

NEW YORK, NY--(Marketwired - April 06, 2016) - PharmaCyte Biotech (OTCQB: PMCB) expects to begin its clinical trial in advanced pancreatic cancer in 2016; however, locking down an exact date has...
June 03, 2015 09:30 ET | Source: PharmaCyte Biotech, Inc.

PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study

NEW YORK, NY--(Marketwired - June 03, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate...
April 23, 2015 09:20 ET | Source: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials

NEW YORK, NY--(Marketwired - April 23, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The...
June 20, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment

NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational...
June 12, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers

NEW YORK, NY--(Marketwired - Jun 12, 2014) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech...
May 23, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients

NEW YORK, NY--(Marketwired - May 23, 2014) - Nuvilex (OTCQB: NVLX) is calling it a "two pronged attack" on pancreatic cancer, but investors may be calling it an "end-around" or another avenue of...